Skip to main content
SpringerLink
Log in

A Risk and Benefit Assessment of Treatment for AIDS-Related Kaposi’s Sarcoma

  • Review Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Kaposi’s sarcoma is the most common malignancy observed in patients with HIV-1 infection, and causes considerable morbidity and, when the lungs are involved, mortality. Therapy should be based on an evaluation of prognostic factors, in particular the extent and rate of tumour growth, patient symptoms, immune system condition and concurrent complications of AIDS. Nevertheless, considering the palliative role of Kaposi’s sarcoma therapy, the potential benefits of therapy must be weighed against the high risk of adverse effects. Therefore, quality of life assessment is an integral component of therapeutic decisions.

Localised Kaposi’s sarcoma cutaneous tumours have been successfully treated with surgical excision, laser therapy, liquid nitrogen cryotherapy and radiotherapy. In patients with moderately extensive cutaneous or mucosal disease and CD4+ cell counts of ≥200/ml, immunotherapy and antiretroviral drugs are indicated. Preliminary results indicate that antiretroviral therapy might be effective and well tolerated in the treatment of less advanced Kaposi’s sarcoma.

In patients with aggressive and extensive mucocutaneous disease or with visceral manifestations of Kaposi’s sarcoma, systemic cytotoxic therapy is indicated. However, the optimal treatment has yet to be found. The combination of doxorubicin, bleomycin and vincristine (ABV) has produced high overall response rates and is indicated as first-line treatment for patients with life-threatening or visceral disease. In patients who are leucopenic and require chemotherapy, single or dual agents associated with lower myelotoxicity [i.e. bleomycin, vincristine/vinblastine or a combination of bleomycin and vincristine/vinblastine (BV)] are most widely used. Other effective cytotoxic regimens are liposomal anthracyclines, paclitaxel and vinorelbine. To date, 3 randomised trials have compared these drugs to ABV and BV. In a large phase III study, the efficacy of liposomal daunorubicin was comparable with that of ABV. In 2 phase III studies, liposomal doxorubicin was compared with ABV and BV regimens and was found to be significantly more effective in producing objective responses. Therefore, liposomal doxorubicin, although more myelosuppressive than the BV regimen, is now considered by many physicians as the first-line therapy in patients with advanced stage Kaposi’s sarcoma.

Paclitaxel and vinorelbine have potential in Kaposi’s sarcoma, but additional studies are needed to evaluate different schedules and to compare their activity with that of the reference regimens.

Institution or continuation of both effective antiretroviral therapy and prophylaxis of opportunistic infections should be recommended to all patients receiving systemic cytotoxic therapies. However, attention must be paid to the crosstoxicity and possible pharmacokinetic interactions between antiretrovirals and antineoplastics.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Gill PS, Hamilton A, Naidu Y. Epidemic (AIDS-related) Kaposi’s sarcoma: epidemiology, pathogenesis and treatment. AIDS Updates 1994; 7: 1–11

    Google Scholar 

  2. Tirelli U, Vaccher E, Lazzarin A, et al. Epidemic Kaposi’s sarcoma in Italy, a country with intravenous drug users as the main group affected by HIV infection. Ann Oncol 1991; 2: 373–6

    PubMed  CAS  Google Scholar 

  3. Beral V, Peterman TA, Berkelman RL, et al. Kaposi’s sarcoma among persons with AIDS: a sexually transmitted infection? Lancet 1990; 335: 123–8

    Article  PubMed  CAS  Google Scholar 

  4. Serraino D, Salariina G, Franceschi S, et al. The epidemiology of AIDS-associated non-Hodgkin’s lymphoma in the World Health Organization European Region. Br Cancer 1992; 66: 912–6

    Article  CAS  Google Scholar 

  5. Brodt HR, Kamps BS, Gute P. Changing incidence of AIDS-defining illness in the era of antiretroviral combination therapy. AIDS 1997; 11: 1731–8

    Article  PubMed  CAS  Google Scholar 

  6. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science 1994; 266: 1865–9

    Article  PubMed  CAS  Google Scholar 

  7. Huang YO, Li JJ, Kaplan MH, et al. Human herpesvirus-like nucleic acid in various forms of Kaposi’s sarcoma. Lancet 1995; 345: 759–61

    Article  PubMed  CAS  Google Scholar 

  8. Su IJ, Hsu YS, Chang YC, et al. Herpesvirus-like DNA sequences in Kaposi’s sarcoma from AIDS and non-AIDS patients in Taiwan. Lancet 1995; 345: 722–3

    Article  PubMed  CAS  Google Scholar 

  9. Rutgers JL, Wieczorek R, Bonetti F, et al. The expression of endothelial cell surface antigens by AIDS-associated Kaposi’s sarcoma: evidence for a vascular endothelial cell origin. Am JPathol 1986; 122: 493–9

    CAS  Google Scholar 

  10. Weich HA, Salahuddin SZ, Gill P, et al. AIDS-associated Kaposi’s sarcoma-derived cells origin in long-term culture express and synthetize smooth muscle alpha-actin. Am J Pathol 1991; 139: 1251–8

    PubMed  CAS  Google Scholar 

  11. Miles SA, Rezai AR, Salazar-Gonzalezs JF, et al. AIDS-related Kaposi’s sarcoma-derived cells produce and respond to interleukin 6. Proc Natl Acad Sci USA 1990; 87: 4068

    Article  PubMed  CAS  Google Scholar 

  12. Molina J-M, Scadden DT, Byrn R, et al. Production of tumor necrosis factor a and interleukin 1b by monocytic cells infected with human immunodeficiency virus. J Clin Invest 1989; 84: 733

    Article  PubMed  CAS  Google Scholar 

  13. Krown S, Metroka C, Wernz J. Kaposi’s sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. J Clin Oncol 1989; 7: 1201–7

    PubMed  CAS  Google Scholar 

  14. Krigel RL, Friedman-Kien A. Kaposi’s sarcoma in AIDS: diagnosis and treatment. 2nd ed. In: De Vita V, Hellman S, Rosenberg SA, editors. AIDS — etiology, diagnosis, treatment and prevention. Philadelphia: JB Lippincott Company, 1988: 245–61

    Google Scholar 

  15. Pluda J, Broder S, Yarchoan R. Therapy of AIDS and AIDS-associated neoplasms. Cancer Chemother Biol Response Modif 1992; 13: 395–439

    Google Scholar 

  16. Buchbinder A, Friedman-Kien A. Clinical aspect of Kaposi’s sarcoma. Curr Opin Oncol 1992; 4: 867–74

    Article  PubMed  CAS  Google Scholar 

  17. Cooper JS, Steinfeld A, Lerch I. Intentions and outcomes in the radiotherapeutic management of epidemic Kaposi’s sarcoma. IntJ Radiat Oncol Biol Phys 1990; 20: 419–22

    Google Scholar 

  18. de Wit R, Smit W, Veenhof K, et al. Palliative radiation therapy for AIDS-associated Kaposi’s sarcoma by using a single fraction of 800 cGy. Radiother Oncol 1990; 19: 131–6

    Article  PubMed  Google Scholar 

  19. Swift PS. The role of radiation therapy in the management of HIV-related Kaposi’s sarcoma. Hematol Oncol Clin North Am 1996; 10: 1069–80

    Article  PubMed  CAS  Google Scholar 

  20. Stelzer KJ, Griffin TW. A randomized prospective trial of radiation therapy for AIDS-associated Kaposi’s sarcoma. Int J Radiat Oncol Biol Phys 1993; 27: 1057–61

    Article  PubMed  CAS  Google Scholar 

  21. Poignonec S, Lachiver LD, Lamas G, et al. Intralesional bleomycin for acquired immunodeficiency syndrome-associated cutaneous KS. Arch Dermatol 1995; 131: 228

    Article  PubMed  CAS  Google Scholar 

  22. Schwartz RA. Kaposi’s sarcoma: advances and perspectives. J Am Acad Dermatol 1996; 34: 804–14

    Article  PubMed  CAS  Google Scholar 

  23. Lilenbaum RC, Ratner S. Systemic treatment of Kaposi’s sarcoma: current status and future directions. AIDS 1994; 8: 141–51

    Article  PubMed  CAS  Google Scholar 

  24. Gill PS, Lunardi-Iskandar Y, Louie S, et al. The effects of preparations of human chorionic gonadotropin of AIDS-related Kaposi’s sarcoma. N Engl J Med 1996; 335: 1261–9

    Article  PubMed  CAS  Google Scholar 

  25. Krown S. Interferon and other biologic agents for the treatment of Kaposi’s sarcoma. Hematol Oncol Clin North Am 1991; 5: 311–22

    PubMed  CAS  Google Scholar 

  26. Kovacs J, Deyton L, Davey R, et al. Combined zidovudine and Interferon-α therapy in patients with Kaposi sarcoma and the Acquired Immunodeficiency Syndrome (AIDS). Ann Intern Med 1989; 111: 280–7

    PubMed  CAS  Google Scholar 

  27. Krown S, Gold J, Niedzwiecki D, et al. Interferon-α with zidovudine: safety, tolerance, and clinical and virologic effects in patients with Kaposi sarcoma associated with the Acquired Immunodeficiency Syndrome (AIDS). Ann Intern Med 1990; 112: 812–21

    PubMed  CAS  Google Scholar 

  28. Fischl M, Uttamchandani R, Resnick L, et al. A phase I study of recombinant human interferon-α2a or human lymphoblastoid interferon-αn 1 and concomitant zidovudine in patients with AIDS-related Kaposi’s sarcoma. J AIDS 1991; 4: 1–10

    CAS  Google Scholar 

  29. Fischl MA, Finkelstein DH, He W, et al. A phase II study of recombinant human interferon alpha 2a and zidovudine in patients with AIDS-related Kaposi’s sarcoma. J Acquir Immune Defic Syndr 1996; 11: 379–84

    Article  CAS  Google Scholar 

  30. Scadden D, Bering H, Levine J, et al. Granulocyte-macrophage colony stimulating factor mitigates the neutropenia of combined interferon alfa and zidovudine treatment for acquired immunodeficiency-associated Kaposi’s sarcoma. J Clin Oncol 1991; 9: 802–8

    PubMed  CAS  Google Scholar 

  31. Krown S, Paredes J, Bundow D, et al. Interferon-α, zidovudine and granulocyte-macrophage colony stimulating factor: a phase I AIDS clinical trials group study in patients with Kaposi’s sarcoma associated with AIDS. J Clin Oncol 1992; 10: 1344–51

    PubMed  CAS  Google Scholar 

  32. Yarchoan R, Broder S. Preliminary results on the use of dideoxynucleosides in the therapy of AIDS. In: Chanock RM, Lerner RA, Brow F, et al., editors. Vaccines 87: modem approaches to new vaccines. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory, 1987

    Google Scholar 

  33. Yarchoan R, Klecker RW, Weinhold KJ, et al. Administration of 3’-azido-3’-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet 1986; I: 575

    Article  Google Scholar 

  34. Murphy M, Armstrong D, Sepkowitz KA, et al. Regression of AIDS-related Kaposi’s sarcoma following treatment with an HIV-1 protease inhibitor. AIDS 1997; 11: 261–2

    PubMed  CAS  Google Scholar 

  35. Conant MA, Opp KM, Poretz D, et al. Reduction of Kaposi’s sarcoma lesions following treatment of AIDS with ritonavir. AIDS 1997; 11: 1300–1

    PubMed  CAS  Google Scholar 

  36. Tavio M, Spina M, Errante D, et al. Feasibility and activity of highly active antiretroviral therapy (HAART) in patients with HIV infection and Kaposi’s sarcoma (KS): preliminary results [abstract 226]. Sixth European Conference on Clinical Aspects and Treatment of HIV-infection; 1997 Oct 11–15; Hamburg, Germany

  37. Volm MD, Wernz J. Patients with advanced AIDS-related Kaposi’s sarcoma (EKS) no longer require systemic therapy after introduction of effective antiretroviral therapy [abstract 162]. American Society of Clinical Oncology; 1997 May 17–20; Denver

  38. Mintzer D, Real FX, Jovino L, et al. Treatment of Kaposi’s sarcoma and thrombocytopenia with vincristine in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1985; 102: 200–2

    PubMed  CAS  Google Scholar 

  39. Rieber E, Mittelman A, Wormser GP, et al. Vincristine and Kaposi’s sarcoma in the acquired immunodeficiency syndrome. Ann Intern Med 1984; 101: 876

    PubMed  CAS  Google Scholar 

  40. Lassoued K, Clauvel JP, Katlama C, et al. Treatment of the acquired immunodeficiency syndrome-related Kaposi’s sarcoma with bleomycin as a single agent. Cancer 1990; 66: 1869–72

    Article  PubMed  CAS  Google Scholar 

  41. Remick SC, Reddy M, Herman D, et al. Continuous infusion bleomycin in AIDS-related Kaposi’s sarcoma. J Clin Oncol 1994; 12: 1130–6

    PubMed  CAS  Google Scholar 

  42. Laubenstein LJ, Krigel RL, Odajnyk CM, et al. Treatment of epidemic Kaposi’s sarcoma with etoposide or a combination of doxorubicin, bleomycin and vinblastine. J Clin Oncol 1984; 2: 1114–8

    Google Scholar 

  43. Schwartsmann G, Sprinz E, Kromfield M, et al. Clinical and pharmacokinetic study of oral etoposide in patients with AIDS-related Kaposi’s sarcoma with no prior exposure to cytotoxic therapy. J Clin Oncol 1997; 15: 2118–24

    PubMed  CAS  Google Scholar 

  44. Schwartsmann G, Sprinz E, Kronfeld M, et al. Phase II study of teniposide in patients with AIDS-related Kaposi’s sarcoma. Eur J Cancer 1991; 27: 1637–9

    Article  PubMed  CAS  Google Scholar 

  45. Volberding P, Abrams D, Conant M, et al. Vinblastine therapy for Kaposi’s sarcoma in the acquired immunodeficiency syndrome. Ann Intern Med 1985; 103: 335–8

    PubMed  CAS  Google Scholar 

  46. Gill P, Rarick M, McCutchan A, et al. Systemic treatment of AIDS-related Kaposi’s sarcoma: results of a randomized trial. Am J Med 1991; 90: 427–33

    PubMed  CAS  Google Scholar 

  47. Shepherd FA, Burkes RL, Ke P, et al. A phase II study of 4’-epirubicin in the treatment of poor-risk Kaposi’s sarcoma and AIDS. AIDS 1991; 5: 305–9

    Article  PubMed  CAS  Google Scholar 

  48. Fischl M, Krown S, O’Boyle K, et al, and the AIDS Clinical Trials Group. Weekly doxorubicin in the treatment of patients with AIDS-related Kaposi’s sarcoma. J AIDS 1993; 6: 259–64

    CAS  Google Scholar 

  49. Kaplan L, Abrams D, Volberding P. Treatment of Kaposi’s sarcoma in acquired immunodeficiency syndrome with an alternating vincristine-vinblastine regimen. Cancer Treat Rep 1986; 70: 1121–2

    PubMed  CAS  Google Scholar 

  50. Gompels ML, Hill A, Jenkins P, et al. Kaposi’s sarcoma in HIV infection treated with vincristine and bleomycin. AIDS 1992; 6: 1175–80

    Article  PubMed  CAS  Google Scholar 

  51. Lipman MCI, Swaden LS, Sabin CA, et al. Kaposi’s sarcoma in HIV infection treated with vincristine and bleomycin. AIDS 1993; 7: 592–3

    Article  PubMed  CAS  Google Scholar 

  52. Gill P, Rarick M, Bernstein-Singer M, et al. Treatment of advanced Kaposi’s sarcoma using a combination of bleomycin and vincristine. Am J Clin Oncol 1990; 13: 315–9

    Article  PubMed  CAS  Google Scholar 

  53. Gill PS, Miles SA, Mitsuyasu RT, et al. Phase I AIDS Clinical Trials Group (075) study of doxorubicin, bleomycin and vincristine chemotherapy with zidovudine in the treatment of AIDS-related Kaposi’s sarcoma. AIDS 1994; 8: 1695–9

    Article  PubMed  CAS  Google Scholar 

  54. Gill P, Berstein-Singer M, Espina B, et al. Adriamycin, bleomycin and vincristine chemotherapy with recombinant granulocyte-macrophage colony-stimulating factor in the treatment of AIDS-related Kaposi’s sarcoma. AIDS 1992; 6: 1477–81

    Article  PubMed  CAS  Google Scholar 

  55. Gill PS, Mitsuyasu RT, Montgomery T, et al. AIDS Clinical Trials Group Study 094: a phase I/II trial of ABV chemotherapy with zidovudine and recombinant human GM-CSF in AIDS-related Kaposi’s sarcoma. Cancer J Sci Am 1997; 3: 278–83

    PubMed  CAS  Google Scholar 

  56. Tavio M, Vaccher E, Antinori A, et al. Combination chemotherapy with doxorubicin, bleomycin, and vindesine for AIDS-related Kaposi’s sarcoma. Cancer 1996; 77: 2117–22

    Article  PubMed  CAS  Google Scholar 

  57. Mitsuyasu RT, Gill P, Paredes J, et al. Combination chemotherapy, adriamycin, bleomycin, vincristine (ABV) with dideoxyinosine (ddI) or dideoxycytidine (ddC) in advanced AIDS-related Kaposi’s sarcoma (ACTG 163) [abstract 822]. American Society of Clinical Oncology: 1995 May 20–23; Los Angeles

  58. Gill PS, Espina BM, Cabriales S, et al. A phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin (Daunoxome) in the treatment of advanced AIDS-related Kaposi’s sarcoma. J Clin Oncol 1995; 13: 996–1003

    PubMed  CAS  Google Scholar 

  59. Presant CA, Scolaro M, Kennedy P, et al. Liposomal daunorubicin treatment of HTV-associated Kaposi’s sarcoma. Lancet 1993; 341: 1242–3

    Article  PubMed  CAS  Google Scholar 

  60. Girard P-M, Bouchaud O, Goetschel A, et al. Phase II study of liposomal encapsulated daunorubicin in the treatment of AIDS-associated mucocutaneous Kaposi’s sarcoma. AIDS 1996; 10: 753–7

    Article  PubMed  CAS  Google Scholar 

  61. Gill PS, Wernz J, Scadden DT, et al. Randomized phase III trial of liposomal daunorubicin (DaunoXome) versus doxorubicin, bleomycin, vincristine (ABV) in AIDS-related Kaposi’s sarcoma. J Clin Oncol 1996; 14: 2353–4

    PubMed  CAS  Google Scholar 

  62. Coukell AJ, Spencer CM. Polyethilene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi’s sarcoma. Drugs 1997; 53: 520–38

    Article  PubMed  CAS  Google Scholar 

  63. Jie C, Tulpule A, Zheng T, et al. Treatment of epidemic (AIDS-related) Kaposi’s sarcoma. Curr Opin Oncol 1997; 9: 433–9

    Article  PubMed  CAS  Google Scholar 

  64. Goebel F-D, Goldstein D, Goos M, et al. Efficacy and safety of Stealth® liposomal doxorubicin in AIDS-related Kaposi’s sarcoma. Br J Cancer 1996 73: 989–94

    Article  PubMed  CAS  Google Scholar 

  65. Harrison M, Tomlinson D, Stewart S. Liposomal-entrapped doxorubicin: an active agent in AIDS-related kaposi’s sarcoma. J Clin Oncol 1995; 13: 914–20

    PubMed  CAS  Google Scholar 

  66. Bogner JR, Kronawitter U, Rolinski B, et al. Liposomal doxorubicin in the treatment of advanced AIDS-related Kaposi’s sarcoma. J AIDS 1994; 7: 463–8

    CAS  Google Scholar 

  67. Berry G, Billingham M, Alderman E, et al. The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi’s sarcoma patients treated with pegylated liposomal doxorubicin. Ann Oncol 1998; 9: 711–6

    Article  PubMed  CAS  Google Scholar 

  68. Northfelt DW, Dezube BJ, Thommes JA, et al. Pegylated-liposomal doxorubicin, bleomycin and vincristine in the treatment of AIDS-related Kaposi’s sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 1998; 7: 2445–51

    Google Scholar 

  69. Northfelt DW, Dezube BJ, Thommes JA, et al. Efficacy of PEG-coated liposomal doxorubicin in the treatment of AIDS-related Kaposi’s sarcoma after failure of standard chemotherapy. J Clin Oncol 1997; 15: 653–60

    PubMed  CAS  Google Scholar 

  70. Stewart S, Jablonowski H, Goebel FD, et al. Randomized comparative trial of PEG-coated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi’s sarcoma. J Clin Oncol 1998; 16: 683–91

    PubMed  CAS  Google Scholar 

  71. Spencer CM, Faulds D. Paclitaxel. Areview of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs 1994; 48: 794–847

    Article  PubMed  CAS  Google Scholar 

  72. Rowinsky EK, Cazenave LA, Donehower RC. Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 1990; 82: 1247–59

    Article  PubMed  CAS  Google Scholar 

  73. Ritonavir (Norvir) package insert. Abbot Laboratories, North Chicago (IL), 1996

  74. Saville MW, Lietzau J, Pluda JM, et al. Treatment of HTV-associated Kaposi’s sarcoma with paclitaxel. Lancet 1995, 346: 26–8

    Article  PubMed  CAS  Google Scholar 

  75. Welles L, Saville W, Lietzau J, et al. Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi’s sarcoma. J Clin Oncol 1998; 16: 1112–21

    PubMed  CAS  Google Scholar 

  76. Gill PS, Scadden DT, Groopman J, et al. Low dose paclitaxel (Taxol®) is highly effective in the treatment of patients with advanced AIDS-related Kaposi’s sarcoma [abstract no. 77]. Proceedings of the National AIDS Malignancy Conference; 1997 Apr 28–30: Bethesda (MD)

    Google Scholar 

  77. Hohneker JA. A summary of vinorelbine (Navelbine) safety data from North American Clinical Trials. Semin Oncol 1994; 21 Suppl. 10: 42–7

    PubMed  CAS  Google Scholar 

  78. Errante D, Fasan M, Rizzardini G, et al. Evidence of activity of vinorelbine in patients with previously treated AIDS-associated Kaposi’s sarcoma. AIDS 1996; 10: 1742–3

    Article  PubMed  CAS  Google Scholar 

  79. Bouscarat F, Dazza MC, Melchiro JC, et al. Kaposi’s sarcoma and sex hormones. AIDS 1997; 11: 687–8

    PubMed  CAS  Google Scholar 

  80. Klauke S, Schoefer H, Althoff PH, et al. Sex hormones as a cofactor in the pathogenesis of epidemic KS. AIDS 1995; 9: 1295–6

    Article  PubMed  CAS  Google Scholar 

  81. Lunardi-Iskandar Y, Bryant JT, Zeman RA, et al. Tumorigenesis and metastasis of neoplastic Kaposi’s sarcoma cell line in immunodeficient mice blocked by a human pregnancy hormone. Nature 1995; 375: 64–9

    Article  PubMed  CAS  Google Scholar 

  82. Harris PJ. Treatment of Kaposi’s sarcoma and other manifestations of AIDS with human chorionic gonadotropin. Lancet 1995; 346: 118–9

    Article  PubMed  CAS  Google Scholar 

  83. Tirelli U, Tavio M, Giacca M, et al. Human chorionic gonadrotopin in the treatment of HIV-related Kaposi’s sarcoma. AIDS 1997; 11: 387–8

    PubMed  CAS  Google Scholar 

  84. Yamaguchi NH, Varella D, Guerra CVC, et al. Acase report with unexpected adverse events in one AIDS-related Kaposi’s sarcoma treated with beta human chorionic gonadotropin (beta-HCG) [abstract #867]. American Society of Clinical Oncology; 1996 May 18–21: Philadelphia (PA)

    Google Scholar 

  85. Jones JL, Hanson DL, Chu SY, et al. AIDS-associated Kaposi’s sarcoma. Science 1995; 267: 1078–9

    Article  PubMed  CAS  Google Scholar 

  86. Costagliola D, Mary-Kraus M. Can antiretroviral agents decrease the occurrence of Kaposi’s sarcoma? Lancet 1995; 346: 578

    Article  PubMed  CAS  Google Scholar 

  87. Mocroft A, Youle M, Gazzard B, et al. Anti-herpes virus treatment and risk of Kaposi’s sarcoma in HIV infection. AIDS 1996; 10: 1101–5

    Article  PubMed  CAS  Google Scholar 

  88. Morfeldt L, Torssander J. Long term remission of Kaposi’s sarcoma following foscarnet treatment in HIV-infected patients. Scand J Infect Dis 1994; 26: 749–52

    Article  PubMed  CAS  Google Scholar 

  89. Kedes DH, Ganem D. Sensitivity of Kaposi’s sarcoma-associated herpesvirus replication to antiviral drugs. J Clin Invest 1997; 99: 2082–6

    Article  PubMed  CAS  Google Scholar 

  90. Humphrey RW, O’Brien TR, Newcomb FM, et al. Kaposi’s sarcoma (KS)-associated herpesvirus-like DNA sequences in peripheral blood mononuclear cells: association with KS and persistence in patients receiving anti-herpesvirus drugs. Blood 1996; 88: 297–301

    PubMed  CAS  Google Scholar 

  91. Tan B, Ratner L. The use of new antiretroviral therapy in combination with chemotherapy. Curr Opin Oncol 1997; 9: 455–64

    Article  PubMed  CAS  Google Scholar 

  92. Sparano JA, Sarta C. Infection prophylaxis and antiretroviral therapy in patients with HIV infection and malignancy. Curr Opin Oncol 1996; 8: 392–9

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Medical Oncology and AIDS, Centro di Riferimento Oncologico, via Pedemontana Occ. le 12, 33081, Aviano, Pordenone, Italy

    Guglielmo Nasti, Domenico Errante, Sandra Santarossa, Emmanuela Vaccher &  Umberto Tirelli

Authors
  1. Guglielmo Nasti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Domenico Errante
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sandra Santarossa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Emmanuela Vaccher
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Umberto Tirelli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Umberto Tirelli.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nasti, G., Errante, D., Santarossa, S. et al. A Risk and Benefit Assessment of Treatment for AIDS-Related Kaposi’s Sarcoma. Drug-Safety 20, 403–425 (1999). https://doi.org/10.2165/00002018-199920050-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199920050-00002

Keywords

Search

Navigation